1. Home
  2. SKYE vs HURC Comparison

SKYE vs HURC Comparison

Compare SKYE & HURC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYE
  • HURC
  • Stock Information
  • Founded
  • SKYE 2012
  • HURC 1968
  • Country
  • SKYE United States
  • HURC United States
  • Employees
  • SKYE N/A
  • HURC N/A
  • Industry
  • SKYE Biotechnology: Pharmaceutical Preparations
  • HURC Industrial Machinery/Components
  • Sector
  • SKYE Health Care
  • HURC Industrials
  • Exchange
  • SKYE Nasdaq
  • HURC Nasdaq
  • Market Cap
  • SKYE 108.5M
  • HURC 125.1M
  • IPO Year
  • SKYE N/A
  • HURC N/A
  • Fundamental
  • Price
  • SKYE $4.07
  • HURC $17.55
  • Analyst Decision
  • SKYE Buy
  • HURC
  • Analyst Count
  • SKYE 7
  • HURC 0
  • Target Price
  • SKYE $15.50
  • HURC N/A
  • AVG Volume (30 Days)
  • SKYE 296.3K
  • HURC 34.2K
  • Earning Date
  • SKYE 11-06-2025
  • HURC 09-05-2025
  • Dividend Yield
  • SKYE N/A
  • HURC N/A
  • EPS Growth
  • SKYE N/A
  • HURC N/A
  • EPS
  • SKYE N/A
  • HURC N/A
  • Revenue
  • SKYE N/A
  • HURC $186,789,000.00
  • Revenue This Year
  • SKYE N/A
  • HURC N/A
  • Revenue Next Year
  • SKYE N/A
  • HURC N/A
  • P/E Ratio
  • SKYE N/A
  • HURC N/A
  • Revenue Growth
  • SKYE N/A
  • HURC N/A
  • 52 Week Low
  • SKYE $1.14
  • HURC $13.19
  • 52 Week High
  • SKYE $6.13
  • HURC $23.76
  • Technical
  • Relative Strength Index (RSI)
  • SKYE 59.48
  • HURC 46.89
  • Support Level
  • SKYE $3.96
  • HURC $17.19
  • Resistance Level
  • SKYE $4.35
  • HURC $18.43
  • Average True Range (ATR)
  • SKYE 0.29
  • HURC 0.92
  • MACD
  • SKYE 0.07
  • HURC 0.06
  • Stochastic Oscillator
  • SKYE 62.20
  • HURC 50.88

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About HURC Hurco Companies Inc.

Hurco Companies Inc is a United States-based industrial technology company. It designs, manufactures, and sells computerized machine tools, consisting mainly of vertical machining centers and turning centers, to companies in the metalworking industry through sales, service, and distribution networks. The company concentrated on designing user-friendly computer control systems that both skilled and unskilled machine tool operators can operate. It generates maximum revenue from the Computerized Machine Tools product. Geographically, It derives a majority of its revenue from the United States of America. Its product categories include 5-Axis VMC; 3-Axis VMC; Horizontal MC and Turning Centers.

Share on Social Networks: